Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Acute Bacterial Skin And Skin Structure Infections Market Grown from 2024 to 2025?

The market size for acute bacterial skin and skin structure infections has seen a significant surge in the past few years. It is projected to escalate from $11.75 billion in 2024 to $13.03 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.9%. The market expansion in the past was driven by innovation in the healthcare sector, economic conditions, patient population dynamics, advancements in diagnostic techniques, and innovation in clinical trials.

What Growth Rate Is Anticipated for the Acute Bacterial Skin And Skin Structure Infections Market in the Coming Years?

The market for acute bacterial skin and skin structure infections is anticipated to witness significant expansion in the forthcoming years, with its value expected to surge to $18.99 billion by 2029 at a 9.9% CAGR. The anticipated growth over the forecast period is attributable to global epidemiological influences, the introduction of new therapies in the market, fast diagnostic tools, a patient-focused methodology, and evolving treatment guidelines. Key trends during the forecast period encompass the demographics of the patient population, concerns pertaining to antibiotic resistance, the advent of improved treatment tactics, the prevalence of methicillin-resistant staphylococcus aureus (MRSA), and an emphasis on outpatient care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Who Are the Leading Companies in the Acute Bacterial Skin And Skin Structure Infections Market?

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

What Are the Key Drivers of the Acute Bacterial Skin And Skin Structure Infections Market?

The surge in skin infections is anticipated to fuel the growth of the acute bacterial skin and skin structure infections market. These infections, caused by microorganisms including bacteria, fungi, or viruses, can create uncomfortable symptoms as they invade and multiply within the skin. The escalating number of skin infections generates more demand for therapeutic solutions, antibiotics, and innovative treatments that address acute bacterial skin and skin structure infections, thereby enabling patient access to top-tier care and health results. For instance, the World Health Organization noted in March 2023 that about 1.8 billion people worldwide experience skin conditions at any given time. Around 10% of these cases are Neglected Tropical Diseases (NTDs), with fungal and bacterial infections making up 34% and 23% respectively, often resulting in high death rates. Consequently, the escalating incidence of skin infections fuels the growth trajectory of the acute bacterial skin and skin structure infections market. An uptick in chronic diseases is predicted to spur the growth of the acute bacterial skin and skin structure infections market. Chronic diseases encompass prolonged medical conditions that typically progress at a slow pace and persist for a considerable time. These diseases, which often last for years or even a lifetime, usually don’t resolve on their own. The proliferation of chronic diseases propels the acute bacterial skin and skin structure infections market by increasing the chance of bacterial skin infections, thereby requiring more treatments, hospital stays, specialized healthcare, research, patient education, health expenditures, and individualized interventions. In September 2022, the World Health Organization reported 41 million deaths, accounting for 74% of deaths from non-communicable or chronic diseases worldwide annually. These included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Hence, the growing prevalence of chronic diseases is a key driver for the growth of the acute bacterial skin and skin structure infections market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp

What Are the Key Market Segments in the Acute Bacterial Skin And Skin Structure Infections Industry?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

What Are the Latest Trends in the Acute Bacterial Skin And Skin Structure Infections Market?

Leading firms in the acute bacterial skin and skin structure infections market are adopting a strategic approach of introducing innovative single-dose treatments such as Dalbonova, in an effort to strengthen their market position. Dalbonova is a single-dose therapy designed to provide both effectiveness and convenience, enabling patients to accomplish their anticipated outcomes with a single powerful dose of 1500 mg that is administered just once. For example, BDR Pharmaceuticals Internationals Pvt. Ltd., a pharmaceutical company from India renowned for its speciality in API (active pharmaceutical ingredient) and formulation therapeutic areas, including acute bacterial skin and skin structure infections, introduced the Dalbonova injection to the market in August 2023. By providing a single-dose treatment, the Dalbonova Injection minimizes the potential for hospital-acquired diseases and removes the necessity for hospital admissions. This product is specifically for treating acute bacterial skin and skin structure infections (ABSSSI) initiated by specific gram-positive microorganisms and is recommended for patients of all age groups, including newborns.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

What Are the Key Regional Markets in the Acute Bacterial Skin And Skin Structure Infections Industry?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

This Report Delivers Insight On:

1. How big is the acute bacterial skin and skin structure infections market, and how is it changing globally?

2. Who are the major companies in the acute bacterial skin and skin structure infections market, and how are they performing?

3. What are the key opportunities and risks in the acute bacterial skin and skin structure infections market right now?

4. Which products or customer segments are growing the most in the acute bacterial skin and skin structure infections market?

5. What factors are helping or slowing down the growth of the acute bacterial skin and skin structure infections market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model